Itacitinib
Leukemia, Acute
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 26/ 100
- Competitive Position
- 89/ 100
Competitive context
59 Active assets in the Leukemia, Acute cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sawa Ito, MD | Phase 2/3 | BB |
Cyclophosphamide Sawa Ito, MD | Phase 4 | BB |
Cytosin-Arabinosid Janssen Research & Development, LLC | Phase 2/3 | BB |
Busulphan Sawa Ito, MD | Phase 4 | BB |
ETOPOSIDE Nanfang Hospital, Southern Medical University | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
Itacitinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →